KEISHA YARBOROUGH: Open Payments
NPI 1982229464 · ORANGEBURG, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$388 in 14 payments from 7 companies in 2025. Trend: 2023 $252 · 2024 $720 · 2025 $388
Food & beverage: $388
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 1 | $125 |
| Neurocrine BioSciences, Inc. | 4 | $88 |
| Alkermes, Inc. | 3 | $61 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Supernus Pharmaceuticals, Inc. | 2 | $38 |
| Janssen Pharmaceuticals, Inc | 1 | $23 |
| ABBVIE INC. | 1 | $16 |
Products named: REXULTI, INGREZZA, ARISTADA, Qelbree, INVEGA SUSTENNA, UZEDY, AUSTEDO XR, VRAYLAR.
Industry payments across SC — which companies pay providers there.
